EUCTR2011-000854-44-NO进行中（未招募）1 期
A Two Part, Multi-Centre, Randomized, Placebo-Controlled, Double-Blind Study of TRK-170 for the Treatment of Crohn's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 237
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient has to meet all of the following criteria to be eligible to enter the study:
- •1) Male and female patients aged 18 to 50 years
- •2) Patient has a diagnosis of CD at least 4 months prior but not more than 10 years before screening. The diagnosis should have been confirmed by endoscopic findings including histological examination
- •3) Patient has had disease activity with lesions in the colon within the past 12 months before dosing, as confirmed by ileocolonoscopy
- •4) Patient with moderately active CD at time of screening defined as a CDAI score of between 220 and 450
- •5) Patient has stable disease activity (stable for = 2 weeks prior to screening) and not foreseen to require treatment with high dose steroids or other short term, potent treatments (e.g. TNF-a inhibitors) during the study period
- •6) Patient has an increased CRP level (> upper limit of normal) at
- •screening, as a sign of active disease, as judged by the investigator
- •7) Patient with a body weight of greater than 50 kg but less than 120 kg
- •8) Patient willing and able to participate in the study and provide signed informed consent
- •9) Patient agrees to use adequate contraceptive measures, in other words, Female patient who has not been post-menopausal for more than 3 months or female patients of childbearing potential must use adequate contraception (i.e. a method with less than 1% failure rate [e.g. diaphragm or condom used in combination with spermicidal cream, sterilization, an intrauterine device, or a vasectomised partner]) during and for at least 3 months after the last dose of IP. Females using hormonal contraception methods must also use an additional contraception method (as described above) during and for at least 3 months after the last dose of IP
- •Male patient who agrees to use condoms in combination with
- •spermicidal cream during the study and for three months after the last dose of the IP, or patient who has a female partner using adequate contraception as described above
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 609
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patient meeting any of the following criteria will not be permitted to enter the study:
- •1) Increased risk of hypersensitivity or allergy to the IP or placebo product as judged by the investigator
- •2) Patient has had a clinically significant illness within 4 weeks prior to screening, at the investigator's discretion
- •3) Patient with clinically significant deviations in laboratory values as determined by the investigator
- •4) Patient who had a serious infection within 3 months, opportunistic infection within one month, or current signs or symptoms of severe, progressive or uncontrolled disease
- •5) Severe renal impairment defined as a predicted creatinine clearance of 30 mL/min or less, based on the Cockroft-Gault equation
- •6) Patient has a history of cancer or lymphoproliferative disease within the last 5 years
- •7) History of substance or alcohol abuse within the past one year prior to screening
- •8) Positive viral test result for hepatitis B or C or human HIV 1 or 2 or positive pre-study testing for major drugs of abuse or excessive alcohol consumption
- •9) Chest X-ray positive or suspected positive for active tuberculosis
- •10) Female patient currently pregnant or breast-feeding or intending to become pregnant during the study or within three months after the last dose of the IP
- •11) Female patient of childbearing age (unless surgically sterile) without a negative urine pregnancy test at screening and at enrollment
- •12) Patient currently has gastrointestinal disease other than CD (e.g., ulcerative colitis, short bowel syndrome, malabsorption, intestinal obstruction). This includes patients with an ostomy, ileal pouch, a previous ileo-rectal anastomosis, a history of procto-colectomy but not subtotal colectomy, draining fistula or abscess or are receiving enteral nutrition via a feeding tube or parenteral nutrition
- •13) Treatment with immunosuppressants or anti-cancer drugs (e.g., azathioprine, 6-MP, 6-thioguanin, methotrexate, mycophenolate mofetil, sirolimus (rapamycin), tacrolimus, thalidomide, cyclophosphamide, or cyclosporine) within the last 3 months prior to screening
- •14) Treatment with intravenous or rectal steroids for CD, antibiotics (e.g., metronidazole or ciprofloxacin) or continued repeated use of nonsteroidal anti-inflammatory agents (NSAIDs) within 2 weeks prior to screening
- •15) Treatment with Tysabri® or inhibitors of TNF-a within 8 weeks prior to screening
- •16) Treatment with a 5-ASA formulation (oral mesalazine) at a fixed dose of 2.4 g/day or higher (not exceeding the approved dose) within 1 week prior to screening
- •17) Patient who changed the dose of oral corticosteroids within 2 weeks prior to screening or ongoing treatment with prednisolone exceeding 25 mg/day or corresponding doses of other corticosteroids
- •18) Patient who stopped using oral corticosteroids within 4 weeks prior to screening
- •19) Patient has previous treatment failure or had an inadequate response or intolerance to biologic drugs for CD(e.g., Tysabri® or inhibitors of TNF-a)
- •20) Patient who had a previous GI surgical procedure (except
- •appendectomy and ileocecal resection) within 8 weeks of screening or foreseen to need GI surgery during the study
- •21) Patient has contributed blood (e.g., blood donation or clinical study participation) or suffered from blood loss, of at least 450 mL (1 unit of blood) within 90 days before screening or has donated plasma within 7 days prior to screening
- •22) Patient has participated in a clinical study in which he/
研究者
相似试验
进行中（未招募）
不适用
A clinical study for treatment of Crohns Disease with the new drugsubstance TRK-170. The study consists of two parts and are conductedat servral hopsitals in Europe. Patients in the study may receive placebo(drug with no effect) but either the doctor or the patient will knowduring the study.MedDRA version: 13.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's diseaseEUCTR2011-000854-44-HUToray Industries, Inc.609
进行中（未招募）
不适用
A clinical study for treatment of Crohns Disease with the new drug substance TRK-170. The study consists of two parts and are conducted at servral hopsitals in Europe. Patients in the study may receive placebo (drug with no effect) but either the doctor or the patient will know during the study.Crohn's diseaseMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000854-44-LVToray Industries Inc510
进行中（未招募）
1 期
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe AsthmaSevere asthmaMedDRA version: 9.1 Level: LLT Classification code 10003553 Term: AsthmaEUCTR2008-004149-27-FRGlaxoSmithKline Research and Development Ltd
进行中（未招募）
不适用
A multi-centre placebo-controlled clinical study to evaluate the adequate dose, mechanism of action, efficacy, safety and tolerability, absortion, distribution, metabolism and elimination from the body and interaction with the target of namilumab/MT203 at 4 different subcutaneous doses in subjects with moderate to severe psoriasis.PsoriasisMedDRA version: 18.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2013-002806-30-DETakeda Development Centre Europe Ltd.120
进行中（未招募）
不适用
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilumab/MT203 at 4 Different Subcutaneous Doses – together with an Open-Label, Dose-Escalated Extension to Assess Safety and Efficacy of One Year Treatment - in Subjects with Moderate to Severe Chronic Plaque Psoriasis NEPTUNEPsoriasisMedDRA version: 17.1Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2013-002806-30-PLTakeda Development Centre Europe Ltd.100